Table 3.
Clinical and pathologic features of tumors arising in rASH, rNASH, and overlap groups (Mount Sinai cohort)
| rASH | rNASH | rASH v. rNASH |
overlap | |
|---|---|---|---|---|
| Age, y mean (SD) | 59 (9.0) | 69 (5.2) | p=0.0014 | 60 (8.2) |
| M:F ratio | 7:0 | 15:8 | p=0.14 | 15:1 |
| # tumorsmean (SD) | 3.9 ( 1.6) | 2.7 (2.0) | p=0.16 | 2.2 (1.8) |
| Tumor size, cmmean (SD) | 1.5 (0.75) | 2.0 (1.5) | p=0.073 | 2.0 (1.1) |
| Tumor differentiation(per tumor nodule) | p=0.24 | |||
| Well | 1 (4.5%) | 8 (17%) | 14 (52%) | |
| Moderate | 20 (91%) | 34 (71%) | 13 (48%) | |
| Poor | 1 (4.5%) | 6 (12%) | 0 (0%) | |
| Microscopic vascular invasion | 4/7 (57%) | 15/23 (65%) | p=1 | 8/16 (50%) |
| Macroscopic vascular invasion | 1/7 (14%) | 1/23 (4.3%) | p=0.418 | 0/16 (0%) |
| AFP > 9 | 4/6 (67%) | 9/21 (43%) | p=0.39 | 8/16 (50%) |
| Steatohepatic HCC | 6/7 (86%) | 16/23 (70%) | p=1 | 11/16 (69%) |
| Steatohepatic HCC predominant | 3/7 (43%) | 12/23 (52%) | p=1 | 7/16 (43%) |
| Glycogenated hepatocyte nuclei | 4/7 (57%) | 15/23 (65%) | p=1 | 6/16 (38%) |